4MNA Stock Chart & Stats
€3.47
-€0.18(-4.82%)
At close: 4:00 PM EDT
€3.47
-€0.18(-4.82%)
Day’s Range― - ―
52-Week Range€1.63 - €9.85
Previous CloseN/A
Volume0.00
Average Volume (3M)184.00
Market Cap
€222.55M
Enterprise Value€435.40
Total Cash (Recent Filing)€75.27M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 11, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.37
Shares Outstanding47,747,560
10 Day Avg. Volume11
30 Day Avg. Volume184
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.28Price Target Upside109.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal CNS PipelineA continuing Phase 3 program provides a potentially valuable path toward a commercial CNS therapy. Positive trial results could establish product revenue and improve strategic options, although development remains lengthy and execution-dependent.
Accounting LeadershipSeparating accounting leadership from the CFO role may strengthen internal controls, reporting discipline and regulatory readiness. These capabilities are durable advantages for a capital-intensive clinical company reliant on investor and regulator confidence.
Governance FrameworkUpdated governance provisions clarify shareholder processes, legal protections and forum selection while maintaining audit continuity. Better-defined governance can support oversight and reduce structural execution risk as the pipeline advances.
Bears Say
No Recurring RevenueThe company lacks an approved commercial product and recurring sales base, so future funding depends heavily on capital markets or successful clinical development. This leaves results highly exposed to trial outcomes and financing conditions.
Persistent Cash BurnOngoing cash consumption increases the need for repeated financing before any potential product launch. Sustained burn can constrain research priorities, reduce strategic flexibility and make delays or unfavorable capital raising more damaging.
Weak Capital PositionNegative equity signals limited balance-sheet resilience, while the equity program offers liquidity at the cost of potential shareholder dilution. Together, they highlight dependence on external capital to sustain the development pipeline.
Minerva Neurosciences News
4MNA FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was €1.63 and its highest was €9.85 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Minerva Neurosciences’s market cap is €222.55M.
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on Aug 07, 2026. The company reported -€0.121 earnings per share for the quarter, beating the consensus estimate of -€0.167 by €0.046.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate is -0.14.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 47,747,560 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -€0.121 in its last earnings report, beating expectations of -€0.167. Following the earnings report the stock price went up 1.904%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in DE:4MNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Minerva Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.28 (109.90% Upside)
€7.28 (109.90% Upside)
Blogger Sentiment
Bullish
DE:4MNA Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
212.59%
Trailing 12-Months
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
4MNA Stock 12 Month Forecast
Average Price Target
€7.28
▲(109.90% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Pulmatrix
―
Chemomab Therapeutics
―
―
Aspire Biopharma Holdings
―